A cannabis clinical trial is a research study that enrolls volunteers who meet set criteria, Some trials randomly assign participants to groups, and clinical trials require informed consent. Three terms decide most of what you need to know: eligibility, randomization and consent. Trial participation is not established treatment and does not guarantee a benefit, so read any study as an open question that you help answer.
What does eligibility mean in a cannabis trial?
Eligibility is the list of rules that decides who may enroll. Listings set age limits, health conditions and past-use requirements. The UCSD cannabis trial listings show a chronic low back pain study open to “eligible people ages 21-65” and an HIV study open to people “ages 18-65”. The Johns Hopkins Cannabis Science Lab research page describes a smoking study for “People aged 18-65 years who are current daily tobacco smokers with an interest in quitting”, and an alcohol withdrawal study for “Individuals ages 21-65 with Alcohol Use Disorder (AUD) who are interested in treatment”.
Check whether a study is recruiting before you plan around it. The UCSD list was last updated July 24, 2026, and some entries read “Sorry, not yet accepting patients” or “Sorry, currently not accepting new patients, but might later”. The same list names sites in La Jolla and San Diego, California, so location is part of the eligibility check.
What does randomization mean?
In a randomized trial, participants are randomly assigned to a study group. The UCSD HIV study says participants “will be randomly assigned to one of two groups”. A placebo is a comparator used in some trials: an inactive substance given to one group so its results can be compared with the group that receives the study treatment. For what chance does and does not balance between groups, see clinical trial randomization.
Not every cannabis study randomizes. In its report on a Colorado team, UCHealth’s report on marijuana trials says the topical study “is, as so many marijuana studies have been, observational” and “doesn’t assign drugs; rather, participants use whatever topical cannabis product they choose.” By contrast, the UCSD HIV study says participants “will be randomly assigned to one of two groups”, and both groups receive the same treatments in a different order over about 6 weeks. Ask the study team which design it uses.
What does informed consent mean before you join?
Informed consent is the agreement that explains what the study will ask of you, what the risks are, and what you agree to. The FDA cannabis research and drug approval process page says the FDA “requires obtaining the informed consent of trial subjects and human subject protection in the conduct of the clinical trials.” The 2021 review by Cooper and colleagues adds that cannabis study protocols must be scientifically justified, meet the ethical principles of the Belmont Report, and include steps to minimize risk.
Before you sign, ask for the written consent form, read its risk section and count the visits in its schedule.
How are risks and potential benefits explained?
Risks are explained in the consent form, and the listing gives the purpose of the study. The FDA reviews each study application to ensure that proposed trials “do not place human subjects at an unreasonable risk of harm.” That review is a check before a study starts, not a promise about how any one person will fare.
For CBD, the 2021 Cooper and colleagues review reports “signals of potential liver injury, potential male reproductive toxicity, and clinically important drug-drug interactions.” The review adds, “We do not know exactly how serious these signals are.”
Benefits are described as the question a study tests. The UCHealth report says the oral study aims “to determine whether daily treatment with oral cannabis reduces spine pain compared to a placebo.” A listing that describes its purpose this way is describing a test, not a result. A Johns Hopkins pregnenolone study says, in its listing, “This is not a study designed to treat a chronic condition.” For the pain-outcome results themselves, read the full 2021 Cooper and colleagues review rather than relying on any single figure. More on that is in cbd for pain.
Stories from people who used cannabis are a different kind of evidence, and they are not a trial result. See cannabis testimonials vs clinical evidence. If two studies of the same product disagree, why cannabis study results conflict explains the usual reasons.
Cannabis trial design at a glance
Use this table to read any listing the same way: population, formulation, comparator, outcome, duration, harms and certainty.
| Design item | What to look for | Example from the evidence |
|---|---|---|
| Population | Who may join, by age, condition and use | UCSD lists a back pain study for adults ages 21-65 with chronic low back pain, and a Johns Hopkins alcohol withdrawal study for people ages 21-65 with Alcohol Use Disorder. |
| Formulation | The exact product, its THC and CBD content, and how it is taken | UCHealth describes an oral study using two cannabis extracts with varying THC and CBD plus a placebo, and a topical study where participants choose their own products. |
| Comparator | What the other group receives | A placebo in the oral study; vaporized cannabis compared with the opioid oxycodone in Lindley’s first study. |
| Outcome | What is measured and how | Whether daily oral cannabis reduces spine pain compared with placebo; physiologic and subjective symptoms of alcohol withdrawal. |
| Duration | How long each treatment period lasts | About six weeks per treatment in the UCHealth oral study; about 6 weeks in the UCSD HIV study; a six-week treatment period with a two-week follow-up in the UCSD CRPS study. |
| Harms | Which side effects are tracked and reported | UCHealth says researchers are tracking harms or side effects; the 2021 Cooper review reports signals of potential liver injury, male reproductive toxicity and drug interactions with CBD. |
| Certainty | How strong the result is so far | The 2021 Cooper review says evidence on the short- and long-term health effects of cannabis use “remains inconclusive”; check the full review for pain-outcome sizes. |
Do you get paid to join a cannabis trial?
Some listings state a payment. The Johns Hopkins smoking study says “compensation of up to $615 can be earned for completing all portions of the study procedures and following all study requirements.” Its THC and limonene study says “You can earn up to $2330 for completing this study.” The alcohol withdrawal study says “Total compensation of up to $450 can be earned by completing all study procedures.” These are amounts for those studies only, and they are tied to finishing the study.
These listings tie payment to completing study procedures, so count the visits before you commit and check the payment terms in the consent form or with the study team. The Johns Hopkins THC and limonene study “will consist of 7 visits to the lab”, so check the schedule in the listing against your own time.
What is the biggest challenge for cannabis research?
The Cooper and colleagues review names three primary barriers: “the US regulatory status of cannabis and cannabinoids, sources for cannabis and cannabinoid study medications, and limited funding and resources to support studies.” The authors add that “the ultimate limitation to research in this field is the availability of funding.”
How long does it take to start a cannabis study?
Approvals come before any enrollment. The FDA page says “The sponsor must wait 30 calendar days following IND submission before initiating any clinical trials, unless FDA notifies the sponsor that the trials may proceed sooner.” The Cooper review says the DEA step “is a process that takes at least 30 days,” and that state approval “can take several months even if no modifications are required.”
What law applies to cannabis trials as of October 21, 2026?
This is information, not legal advice. The Agriculture Improvement Act of December 2018, known as the 2018 Farm Bill, removed hemp from federal controls under the Controlled Substances Act. The Cooper review says the Farm Bill “stipulates that the FDA’s authorities under the Federal Food, Drug, and Cosmetic Act are unchanged,” so hemp-based drug products face the same requirements as other drugs. UCHealth reports that “A December 2025 executive order aims to reclassify marijuana from a Schedule I drug to Schedule III under the Controlled Substances Act.” Check the FDA cannabis research and drug approval process page for current status before you rely on either point.
Before you join: a short checklist
- Confirm the study is recruiting and that you meet its age and health rules.
- Ask whether you would be randomized, whether a placebo is used, and how the groups are arranged.
- Ask for the written consent form and read the risk section before you sign.
- Count the visits and check any stated payment against them.
- Ask which product and delivery method the study uses.
Your next step is to talk with a treating clinician before you enroll. Bring the listing, the consent form and a list of your current medicines.
By TakeHempGummies.com Consumer Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.